General overview: Biomarkers in neuroscience research

International Review of Neurobiology

Volumn 101, Issue , 2011, Pages 1-17

  Filiou, Michaela D ^a   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Biomarker discovery; Biomarker initiatives; Metabolomics; Neuropsychiatric disorders; Personalized medicine; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

BLOOD ANALYSIS; BOOK; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE MODEL; FUNDING; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; MICROARRAY ANALYSIS; NEUROIMAGING; NEUROPSYCHIATRY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEOMICS; QUALITY CONTROL; STANDARDIZATION; VALIDATION PROCESS;

EID: 80055095426     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387718-5.00001-8     Document Type: Chapter

References (90)

1. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Res. Bull. 2010, 83(3-4):147-161.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC, USA, text revision. 4th edn.
3. Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann. N. Y. Acad. Sci. 1997, 836:158-181.
4. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006, 6(11):3414-3425.
5. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Pütz B., Papiol S., Seaman S., Lucae S., Lucae S., Kohli M.A., Nickel T., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36(12):1319-1325.
6. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Schooley R.T., Spilker B.A., Woodcock J., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3):89-95. Biomarkers Definitions Working Group.
7. Bouayed J., Rammal H., Younos C., Soulimani R. Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. Eur. J. Pharmacol. 2007, 564(1-3):146-149.
8. Brunner J., Bronisch T., Uhr M., Ising M., Binder E., Holsboer F., Turck C.W. Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255(6):438-440.
9. Bystritsky A. Treatment-resistant anxiety disorders. Mol. Psychiatry 2006, 11(9):805-814.
10. Chen Q., Camara A.K.S., Stowe D.F., Hoppel C.L., Lesnefsky E.J. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion. Am. J. Physiol. Cell Physiol. 2007, 292(1):C137-C147.
11. Clark D., Dedova I., Cordwell S., Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol. Psychiatry 2006, 11(5):459-470.
12. Couzin J. Science and commerce. Gene tests for psychiatric risk polarize researchers. Science 2008, 319(5861):274-277.
13. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26(12):1367-1372.
14. Ditzen C., Jastorff A.M., Kessler M.S., Bunck M., Teplytska L., Erhardt A., Krömer S.A., Varadarajulu J., Targosz B.S., Sayan-Ayata E.F., Holsboer F., Landgraf R., et al. Protein biomarkers in a mouse model of extremes in trait anxiety. Mol. Cell. Proteomics 2006, 5(10):1914-1920.
15. Ditzen C., Varadarajulu J., Czibere L., Gonik M., Targosz B.S., Hambsch B., Bettecken T., Kessler M.S., Frank E., Bunck M., Teplytska L., Erhardt A., et al. Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Mol. Psychiatry 2010, 15(7):702-711.
16. Domenici E., Willé D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Brittain C., Rujescu D., Giegling I., Turck C.W., Holsboer F., Bullmore E.T., et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010, 5(2):e9166.
17. English J.A., Pennington K., Dunn M.J., Cotter D.R. The neuroproteomics of schizophrenia. Biol. Psychiatry 2011, 69(2):163-172.
18. Filiou M.D., Bisle B., Reckow S., Teplytska L., Maccarrone G., Turck C.W. Profiling of mouse synaptosome proteome and phosphoproteome by IEF. Electrophoresis 2010, 31(8):1294-1301.
19. Filiou M.D., Turck C.W., Martins-de-Souza D. Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin. Appl. 2011, 5(1-2):38-49.
20. Filiou M.D., Zhang Y., Teplytska L., Reckow S., Gormanns P., Maccarrone G., Frank E., Kessler M.S., Hambsch B., Nussbaumer M., Bunck M., Ludwig T., et al. Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways. Biol. Psychiatry 2011, Jul 24, Epub ahead of print. doi: 10.1016/j.biopsych.2011.06.009.
21. Foster A., Miller del D., Buckley P. Pharmacogenetics and schizophrenia. Clin. Lab. Med. 2010, 30(4):975-993.
22. Frank E., Kessler M.S., Filiou M.D., Zhang Y., Maccarrone G., Reckow S., Bunck M., Heumann H., Turck C.W., Landgraf R., Hambsch B. Stable isotope metabolic labeling with a novel 15N-enriched bacteria diet for improved proteomic analyses of mouse models for psychopathologies. PLoS One 2009, 4(11):e7821.
23. Gill M., Donohoe G., Corvin A. What have the genomics ever done for the psychoses?. Psychol. Med. 2010, 40(4):529-540.
24. Gingrich J.A. Oxidative stress is the new stress. Nat. Med. 2005, 11(12):1281-1282.
25. Gohil V.M., Sheth S.A., Nilsson R., Wojtovich A.P., Lee J.H., Perocchi F., Chen W., Clish C.B., Ayata C., Brookes P.S., Mootha V.K. Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis. Nat. Biotechnol. 2010, 28(3):249-255.
26. Golub Y., Kaltwasser S.F., Mauch C.P., Herrmann L., Schmidt U., Holsboer F., Czisch M., Wotjak C.T. Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. J. Psychiatr. Res. 2011, 45(5):650-659.
27. Gormanns P., Mueller N.S., Ditzen C., Wolf S., Holsboer F., Turck C.W. Phenome-transcriptome correlation unravels anxiety and depression related pathways. J. Psychiatr. Res. 2011, 45(7):973-979.
28. Haegler K., Mueller N.S., Maccarrone G., Hunyadi-Gulyas E., Webhofer C., Filiou M.D., Zhang Y., Turck C.W. QuantiSpec-Quantitative mass spectrometry data analysis of 15N-metabolically labeled proteins. J. Proteomics 2009, 71(6):601-608.
29. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjögren M., Asberg M., Ekman R., Wahlestedt C., Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res. 2004, 38(2):113-121.
30. Hiller K., Hangebrauk J., Jäger C., Spura J., Schreiber K., Schomburg D. MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted GC/MS based metabolome analysis. Anal. Chem. 2009, 81(9):3429-3439.
31. Holmes E., Tsang T.M., Huang J.T., Leweke F.M., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Nicholson J.K., Bahn S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3(8):e327.
32. Holsboer F. How we can realize the promise of personalized antidepressant medicines?. Nat. Rev. Neurosci. 2008, 9(8):638-646.
33. Hovatta I., Tennant R.S., Helton R., Marr R.A., Singer O., Redwine J.M., Ellison J.A., Schadt E.E., Verma I.M., Lockhart D.J., Barlow C. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 2005, 438(7068):662-666.
34. Huang J.T., Leweke F.M., Tsang T.M., Koethe D., Kranaster L., Gerth C.W., Gross S., Schreiber D., Ruhrmann S., Schultze-Lutter F., Klosterkötter J., Holmes E., et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2007, 2(1):e756.
35. Huang J.T., McKenna T., Hughes C., Leweke F.M., Schwarz E., Bahn S. CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects. J. Sep. Sci. 2007, 30(2):214-225.
36. Huber R., Spiegel T., Buchner M., Riepe M.W. Graded reoxygenation with chemical inhibition of oxidative phosphorylation improves posthypoxic recovery in murine hippocampal slices. J. Neurosci. Res. 2004, 75(3):441-449.
37. Jacobs J.M., Adkins J.N., Qian W.J., Liu T., Shen Y., Camp D.G., Smith R.D. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res. 2005, 4(4):1073-1085.
38. Jiang L., Lindpaintner K., Li H.F., Gu N.F., Langen H., He L., Fountoulakis M. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 2003, 25(1):49-57.
39. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., Yolken R.H. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol. Psychiatry 2000, 5(2):142-149.
40. Kaddurah-Daouk R., Kristal B.S., Weinshilboum R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 2008, 48:653-683.
41. Kannel W.B., Castelli W.P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann. Intern. Med. 1979, 90(1):85-91.
42. Karl A., Schaefer M., Malta L.S., Dörfel D., Rohleder N., Werner A. A meta-analysis of structural brain abnormalities in PTSD. Neurosci. Biobehav. Rev. 2006, 30(7):1004-1031.
43. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004, 1(2):189-195.
44. Kedracka-Krok S., Fic E., Jankowska U., Jaciuk M., Gruca P., Papp M., Kusmider M., Solich J., Debski J., Dadlez M., Dziedzicka-Wasylewska M. Effect of chronic mild stress and imipramine on the proteome of the rat dentate gyrus. J. Neurochem. 2010, 113(4):848-859.
45. Kendler K.S., Neale M.C. Endophenotype: a conceptual analysis. Mol. Psychiatry 2010, 15(8):789-797.
46. Koch J.M., Kell S., Hinze-Selch D., Aldenhoff J.B. Changes in CREB-phosphorylation during recovery from major depression. J. Psychiatr. Res. 2002, 36(6):369-375.
47. Koch J.M., Hinze-Selch D., Stingele K., Huchzermeier C., Goder R., Seeck-Hirschner M., Aldenhoff J.B. Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. Psychother. Psychosom. 2009, 78(3):187-192.
48. Kraepelin E. Psychiatry Textbook, Vol. II 1899, Verlag von Johann Ambrosius Barth, Leipzig, Germany. 6th edn.
49. Krömer S.A., Kessler M.S., Milfay D., Birg I.N., Bunck M., Czibere L., Panhuysen M., Putz B., Deussing J.M., Holsboer F., Landgraf R., Turck C.W. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 2005, 25(17):4375-4384.
50. Kuratomi G., Iwamoto K., Bundo M., Kusumi I., Kato N., Iwata N., Ozaki N., Kato T. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol. Psychiatry 2008, 13(4):429-441.
51. Landgraf R., Kessler M.S., Bunck M., Murgatroyd C., Spengler D., Zimbelmann M., Nussbaumer M., Czibere L., Turck C.W., Singewald N., Rujescu D., Frank E. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci. Biobehav. Rev. 2007, 31(1):89-102.
52. Levin Y., Schwarz E., Wang L., Leweke F.M., Bahn S. Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J. Sep. Sci. 2007, 30(14):2198-2203.
53. Liao L.J., Park S.K., Xu T., Vanderklish P., Yates J.R. Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc. Natl. Acad. Sci. USA 2008, 105(40):15281-15286.
54. Maccarrone G., Milfay D., Birg I., Rosenhagen M., Grimm R., Bailey J., Jolotarjova N., Holsboer F., Turck C.W. Mining the human CSF proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 2004, 25(14):2402-2412.
55. Maccarrone G., Turck C.W., Martins-de-Souza D. Shotgun mass spectrometry workflow combining IEF and LC-MALDI-TOF/TOF. Protein J. 2010, 29(2):99-102.
56. Marais L., Hattingh S.M., Stein D.J., Daniels W.M. A proteomic analysis of the ventral hippocampus of rats subjected to maternal separation and escitalopram treatment. Metab. Brain Dis. 2009, 24(4):569-586.
57. Martins-de-Souza D., Gattaz W.F., Schmitt A., Rewerts C., Maccarrone G., Dias-Neto E., Turck C.W. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259(3):151-163.
58. Martins-de-Souza D., Gattaz W.F., Schmitt A., Rewerts C., Marangoni S., Novello J.C., Maccarrone G., Turck C.W., Dias-Neto E. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural Transm. 2009, 116(3):275-289.
59. Martins-de-Souza D., Maccarrone G., Wobrock T., Zerr I., Gormanns P., Reckow S., Falkai P., Schmitt A., Turck C.W. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res. 2010, 44(16):1176-1189.
60. Matigian N., Windus L., Smith H., Filippich C., Pantelis C., McGrath J., Mowry B., Hayward N. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Mol. Psychiatry 2007, 12(9):815-825.
61. Möller H.J., Rujescu D. Pharmacogenetics-genomics and personalized psychiatry. Eur. Psychiatry 2010, 25(5):291-293.
62. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 2005, 8(3):403-410.
63. Otte D.M., Bilkei-Gorzó A., Filiou M.D., Turck C.W., Yilmaz Ö., Holst M.I., Schilling K., Abou-Jamra R., Schumacher J., Benzel I., Kunz W.S., Beck H., et al. Behavioral changes in G72/G30 transgenic mice. Eur. Neuropsychopharmacol. 2009, 19(5):339-348.
64. Pan C., Kora G., McDonald W.H., Tabb D.L., VerBerkmoes N.C., Hurst G.B., Pelletier D.A., Samatova N.F., Hettich R.L. ProRata: a quantitative proteomics program for accurate protein abundance ratio estimation with confidence interval evaluation. Anal. Chem. 2006, 78(20):7121-7131.
65. Pan S., Zhu D., Quinn J.F., Peskind E.R., Montine T.J., Lin B., Goodlett D.R., Taylor G., Eng J., Zhang J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 2007, 7(3):469-473.
66. Pasricha S.R., Flecknoe-Brown S.C., Allen K.J., Gibson P.R., McMahon L.P., Olynyk J.K., Roger S.D., Savoia H.F., Tampi R., Thomson A.R., Wood E.M., Robinson K.L. Diagnosis and management of iron deficiency anaemia: a clinical update. Med. J. Aust. 2010, 193(9):525-532.
67. Pennington K., Beasley C.L., Dicker P., Fagan A., English J., Pariante C.M., Wait R., Dunn M.J., Cotter D.R. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol. Psychiatry 2008, 13(12):1102-1117.
68. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9(2):684-697.
69. Puls I., Gallinat J. The concept of endophenotypes in psychiatric diseases meeting the expectations?. Pharmacopsychiatry 2008, 41(Suppl. 1):S37-S43.
70. Rammal H., Bouayed J., Younos C., Soulimani R. Evidence that oxidative stress is linked to anxiety-related behaviour in mice. Brain Behav. Immun. 2008, 22(8):1156-1159.
71. Riepe M.W., Esclaire F., Kasischke K., Schreiber S., Nakase H., Kempski O., Ludolph A.C., Dirnagl U., Hugon J. Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: " chemical preconditioning" J. Cereb. Blood Flow Metab. 1997, 17(3):257-264.
72. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24(8):971-983.
73. Sah R., Ekhator N.N., Strawn J.R., Sallee F.R., Baker D.G., Horn P.S., Geracioti T.D. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol. Psychiatry 2009, 66(7):705-707.
74. Schutzer S.E., Liu T., Natelson B.H., Angel T.E., Schepmoes A.A., Purvine S.O., Hixson K.K., Lipton M.S., Camp D.G., Coyle P.K., Smith R.D., Bergquist J. Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010, 5(6):e10980.
75. Schwarz E., Bahn S. Biomarker discovery in psychiatric disorders. Electrophoresis 2008, 29(13):2884-2890.
76. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., Rahmoune H., Pietsch S., Leweke F.M., Rothermundt M., Steiner J., Koethe D., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010, 12(5):39-47.
77. Schwarz E., Guest P.C., Rahmoune H., Harris L.W., Wang L., Leweke F.M., Rothermundt M., Bogerts B., Koethe D., Kranaster L., Ohrmann P., Suslow T., et al. Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, Apr 12. (Epub ahead of print).
78. Smart T.G. Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation. Curr. Opin. Neurobiol. 1997, 7(3):358-367.
79. Spadoni L.R., Mclean R.B., Herrmann W.L. A rapid immunological test for the detection of early pregnancy. West. J. Surg. Obstet. Gynecol. 1964, 72:92-97.
80. Staner L. Surrogate outcomes in neurology, psychiatry, and psychopharmacology. Dialogues Clin. Neurosci. 2006, 8(3):345-352.
81. Stolp H.B., Dziegielewska K.M. Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol. Appl. Neurobiol. 2009, 35(2):132-146.
82. Sun J., Jia P., Fanous A.H., van den Oord E., Chen X., Riley B.P., Amdur R.L., Kendler K.S., Zhao Z. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS One 2010, 5(6):e11351.
83. Szego E.M., Janáky T., Szabó Z., Csorba A., Kompagne H., Müller G., Lévay G., Simor A., Juhász G., Kékesi K.A. A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome. Eur. Neuropsychopharmacol. 2010, 20(2):96-111.
84. Takahashi M., Itakura M., Kataoka M. New aspects of neurotransmitter release and exocytosis: regulation of neurotransmitter release by phosphorylation. J. Pharmacol. Sci. 2003, 93(1):41-45.
85. Turck C.W., Maccarrone G., Sayan-Ayata E., Jacob A.M., Ditzen C., Kronsbein H., Birg I., Doertbudak C.C., Haegler K., Lebar M., Teplytska L., Kolb N., et al. The quest for brain disorder biomarkers. J. Med. Invest. 2005, 52(Suppl.):231-235.
86. Turck C.W., Ditzen C., Sayan-Ayata E. Proteomic strategies for biomarker discovery: from differential expression to isoforms to pathways. Biomarkers for Psychiatric Disorders 2008, 57-74. Springer, New York. C.W. Turck (Ed.).
87. van de Bayés A., Lagemaat L.N., Collins M.O., Croning M.D., Whittle I.R., Choudhary J.S., Grant S.G. Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nat. Neurosci. 2011, 14(1):19-21.
88. Williams R., Lim J.E., Harr B., Wing C., Walters R., Distler M.G., Teschke M., Wu C., Wiltshire T., Su A.I., Sokoloff G., Tarantino L.M., et al. A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior. PLoS One 2009, 4:e4649.
89. Zhang Y., Webhofer C., Reckow S., Filiou M.D., Maccarrone G., Turck C.W. A MS data search method for improved 15N-labeled protein identification. Proteomics 2009, 9(17):4265-4270.
90. Zhang, Y., Filiou, M.D., Reckow, S., Gormanns, P., Maccarrone, G., Kessler, M.S., Frank, E., Hambsch, B., Holsboer, F., Landgraf, R., and Turck, CW. Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways. Mol. Cell. Proteomics, in press.